Clinical Trial

Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders

Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026 NEW YORK, NY /…

4 months ago

NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury

Demonstrated significant hearing restoration in blast-induced sensorineural hearing loss modelsPromoted significant functional recovery and axonal regeneration in peripheral nerve injury…

4 months ago

Medicure Reports Financial Results for Quarter Ended June 30, 2025

WINNIPEG, MB / ACCESS Newswire / August 20, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused…

4 months ago

LSPedia and Spring Bio Solution Partner to Advance Pharma Traceability in India

FARMINGTON HILLS, Mich. and MUMBAI, India, Aug. 20, 2025 /PRNewswire/ -- LSPedia, a leading provider of pharmaceutical compliance, serialization, and supply…

4 months ago

Shineco Unveils World’s First On-Chain Cell Asset Tokenization Platform; Strategic Acquisition Expands Global Blockchain-Biotech Network

BEIJING, Aug. 20, 2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a leading innovator in induced pluripotent…

4 months ago

Red Light Holland Applauds HHS Review of Psilocybin Rescheduling Petition, Expresses Optimism for Reversal of Schedule I Classification

Toronto, Ontario--(Newsfile Corp. - August 20, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light…

4 months ago

Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control

--Advances European commercialization strategy following CE mark approval-- ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a…

4 months ago

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage…

4 months ago